SOPHiA GENETICS CEO Jurgi Camblong Sells Shares
Jurgi Camblong, CEO of SOPHiA GENETICS, sold shares on June 25, 2026, in a planned transaction.
Key Points
- Jurgi Camblong, CEO of SOPHiA GENETICS, sold 1,373 shares valued at $7,826 on June 25, 2026, at an average price of $5.70.
- SOPHiA GENETICS operates in the healthcare sector with a market cap of $482.4 million and a 52-week high of $5.94.
- Analysts maintain a strong buy consensus with a mean price target of $8.00 for SOPHiA GENETICS.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jurgi Camblong, the Chief Executive Officer of SOPHiA GENETICS SA, sold 1,373 shares of the company on June 25, 2026. The shares were sold at an average price of $5.70, totaling $7,826. This transaction was part of a pre-planned trading scheme.
Insider Buying and Selling at SOPHiA GENETICS SA
In addition to Jurgi Camblong's sale, other insiders at SOPHiA GENETICS have been active in the market. On June 25, 2026, Chief Medical Officer Philippe Menu sold 5,000 shares at $5.50, and Chief Technology Officer Abhimanyu Verma sold 6,944 shares at $5.51. These transactions were also planned.
SOPHiA GENETICS SA Stock Down 26.5%
Shares of NasdaqGS:SOPH traded near $5.75 on Tuesday. SOPHiA GENETICS has a market capitalization of approximately $482.4 million. The company is not currently profitable, as indicated by its lack of a meaningful P/E ratio. The stock's 52-week range is between $2.81 and $5.94, with a 50-day moving average of $5.07 and a 200-day moving average of $4.72. The company's financials show a current ratio of 2.06 and a quick ratio of 1.71, alongside a debt-to-equity ratio of 136.63.
$SOPH stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 15, 2026, BTIG reiterated its buy rating on SOPHiA GENETICS with a price target of $8.00. The consensus among analysts is a strong buy, with the average target price set at $8.00 from three analyst opinions.
About SOPHiA GENETICS
SOPHiA GENETICS SA is a healthcare technology company based in Rolle, Switzerland. It offers the SOPHiA DDM platform, a cloud-based software that analyzes and generates insights from complex data sets. The platform is used by hospitals, laboratories, and biopharmaceutical companies worldwide. Founded in 2011, the company is led by CEO Mr. George A. Cardoza and employs around 415 people.
Bottom Line
Insider transactions like those of Jurgi Camblong provide a glimpse into the company's internal activities, although they may not always indicate the future direction of the stock. SOPHiA GENETICS continues to be a notable player in the healthcare technology sector, leveraging its cloud-based platform to drive innovation. Investors keep an eye on such developments, alongside analyst ratings, to gauge market sentiment.
Get SOPHiA GENETICS SA alerts
New 13F filings, insider trades, and analyst moves on $SOPH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.